Patents by Inventor Yafeng Xue

Yafeng Xue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted indazoles as IRAK4 inhibitors
    Patent number: 11866405
    Abstract: The present application relates to chemical compounds of Formula (A): and pharmaceutically acceptable salts thereof, wherein X, R1, and R2 are as defined herein. The chemical compounds of Formula (A) inhibit IRAK4 and consequently have potential utility in medicine.
    Type: Grant
    Filed: December 1, 2021
    Date of Patent: January 9, 2024
    Assignee: AstraZeneca AB
    Inventors: Ina Terstiege, Stefan Schiesser, Yafeng Xue, Hui-Fang Chang, Anna Ingrid Kristina Berggren
  • IRAK4 INHIBITORS
    Publication number: 20220185817
    Abstract: The present application relates to chemical compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit IRAK4 and consequently have potential utility in medicine.
    Type: Application
    Filed: December 1, 2021
    Publication date: June 16, 2022
    Inventors: Ina TERSTIEGE, Stefan SCHIESSER, Yafeng XUE, Hui-Fang CHANG, Anna Ingrid Kristina BERGGREN
  • New Compounds
    Publication number: 20090149460
    Abstract: The present invention provides new compounds of formula Ia and Ib: as well as a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.
    Type: Application
    Filed: June 17, 2008
    Publication date: June 11, 2009
    Inventors: Stefan Berg, Sven Hellberg, Martin Nylof, Yafeng Xue
  • 3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3
    Patent number: 7399780
    Abstract: The present invention provides new compounds of formula Ia and Ib: as well as a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: July 15, 2008
    Assignee: AstraZeneca AB
    Inventors: Stefan Berg, Sven Hellberg, Martin Nylöf, Yafeng Xue
  • Compounds
    Publication number: 20050153987
    Abstract: The present invention provides new compounds of formula Ia and Ib: as well as a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.
    Type: Application
    Filed: March 28, 2003
    Publication date: July 14, 2005
    Inventors: Stefan Berg, Sven Hellberg, Martin Nylof, Yafeng Xue
  • Novel compounds
    Publication number: 20050075334
    Abstract: The present invention relates to new compounds of formula (I) wherein R1, R2, R3, R4, R5 and A are defined as in formula (I), a process for their preparation and new intermediate prepared therein, pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy, especially in the treatment of c-Jun N-terminal kinase (JNK) mediated conditions in mammals, particularly Alzheimer's Disease.
    Type: Application
    Filed: December 18, 2002
    Publication date: April 7, 2005
    Inventors: Sarah King, Simon Teague, Yafeng Xue, Britt-Marie Swahn
  • Crystal structure of glutamate racemase (MurI)
    Publication number: 20050037478
    Abstract: The present invention discloses crystals of MurI from Gram negative, Gram positive, and atypical bacterium; computer-assisted method for screening, identifying, and designing inhibitors of MurI; inhibitors of MurI; and uses thereof.
    Type: Application
    Filed: December 5, 2003
    Publication date: February 17, 2005
    Applicant: AstraZeneca AB
    Inventors: Marie Anderson, Stewart Fisher, Rutger Folmer, Gunther Kern, Rolf Lundqvist, David Newton, Yafeng Xue